Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial
Addiction and Health · 03.11.2025 · 17 · 1667
DOI: 10.34172/ahj.1667 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Addiction and Health, online erschienen am 03.11.2025. Verfasst von Mehrdad Sinaeinejad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is a common liver disorder associated with metabolic abnormalities. This study aimed to evaluate the effectiveness of N-acetylcysteine (NAC) in improving liver function and metabolic profile in patients with MASLD.
Methods
In this randomized controlled trial (RCT), 69 patients with MASLD were randomly assigned to either the NAC group (600 mg, administered three times daily, n=34) or the placebo group (n=35) for eight weeks. The severity of hepatic steatosis, liver enzymes, and metabolic profile were measured at baseline and the final trial. Data were analyzed using SPSS.
Findings
Following eight weeks of NAC administration in patients with MASLD, no significant changes were observed compared to the placebo in hepatic steatosis grade (P=0.215), serum aspartate aminotransferase (AST) (P=0.21), alanine transaminase (ALT) (P=0.28), malondialdehyde (MDA) (P=0.79), total antioxidant capacity (TAC) (P=0.56), triglycerides (P=0.15), total cholesterol (P=0.28), low-density lipoprotein cholesterol (P=0.32), and high-density lipoprotein cholesterol (P=0.16). However, NAC administration resulted in significant reductions in fasting blood glucose (FBG) (P=0.01), fasting insulin levels (P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran.
- Faculty of Medicine, Bogomolets National Medical University (NMU), Kyiv, Ukraine.
- Department of Hematology-Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
- Faculty of Medicine, Hamadan University of Medical Sciences (UMSHA), Hamadan, Iran.
- Faculty of Medicine, Islamic Azad University, Tehran Medical Sciences Branch (IAUTMU), Tehran, Iran.
- School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
ORCID-Profile: Mehdi Karimi, Masoud Mortezazadeh, Niyousha Shirsalimi, Samira Pirzad
Zitieren
APA
Sinaeinejad, M., Karimi, M., Razavizadeh, M., Arj, A., Tabatabaei, S. H., Mortezazadeh, M., Shirsalimi, N., Pirzad, S., Mofidi, A., & Kashani, M. (2025). Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial. Addiction and Health, 17, 1667. https://doi.org/10.34172/ahj.1667
Vancouver
Sinaeinejad M, Karimi M, Razavizadeh M, Arj A, Tabatabaei SH, Mortezazadeh M, et al. Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial. Addiction and Health. 2025;17:1667. doi:10.34172/ahj.1667
BibTeX
@article{Sinaeinejad2025,
author = {Sinaeinejad, Mehrdad and Karimi, Mehdi and Razavizadeh, Mohsen and Arj, Abbas and Tabatabaei, Seyyed Hamed and Mortezazadeh, Masoud and Shirsalimi, Niyousha and Pirzad, Samira and Mofidi, Abbas and Kashani, Mehdi},
title = {Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial},
journal = {Addiction and Health},
year = {2025},
volume = {17},
pages = {1667},
doi = {10.34172/ahj.1667}
}
EUVIMED